Glycopyrrolate/indacaterol

Drug Profile

Glycopyrrolate/indacaterol

Alternative Names: Indacaterol maleate/glycopyrronium bromide; Indacaterol/glycopyrrolate; Indacaterol/NVA-237; NVA-237/indacaterol; NVA-237/QAB-149; QVA-149; Ultibro Breezhaler; Ultibro Inhalation Capsules; Ulunar Breezhaler; Utibron Neohaler; Xoterna Breezhaler

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Arakis Ltd; Novartis; Vectura
  • Developer Novartis; Pfizer
  • Class Antiasthmatics; Antispasmodics; Bronchodilators; Indans; Pyrrolidines; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease

Most Recent Events

  • 10 Jan 2017 Vectura intends to market glycopyrrolate/indacaterol (Seebri™ Neohaler®) in the first half of 2017 in USA
  • 21 Dec 2016 Glycopyrrolate/indacaterol licensed to Sunovion Pharmaceuticals in USA
  • 05 Sep 2016 Updated efficacy and adverse events data from the phase III FLAME trial in Chronic obstructive pulmonary disease released by Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top